Skip to main content
Premium Trial:

Request an Annual Quote

BGI, Maxwell Plus Form Prostate Cancer Research Alliance

NEW YORK (GenomeWeb) — BGI and Maxwell Plus announced this week that they have partnered to develop a risk model to predict the likelihood a prostate cancer patient will develop advanced or metastatic disease.

Under the terms of the deal, the companies will use Brisbane, Australia-based Maxwell's artificial intelligence technology to analyze data from patient samples sequenced on BGI's MGISEQ-2000 instrument. The sequencing will be carried out at Shenzhen, China-based BGI's Australian lab. Additional terms were not disclosed.

The partners are aiming to better understand the genetic makeup of prostate cancer patients and to investigate the association between prostate, breast, ovarian, and colorectal cancers in the families of patients. They will then combine genetic risk and family history into a risk model for predicting advanced or metastatic prostate cancer.

"The combination of artificial intelligence and genetic sequencing data promises to be an exciting step forward in the management of prostate cancer," BGI Australia Research Director Lynn Fink noted in a statement.